Manufacturer of Controlled Substances; Notice of Application, 24313 [E8-9696]
Download as PDF
<![CDATA[
24313
Federal Register / Vol. 73, No. 86 / Friday, May 2, 2008 / Notices
to be issued by the Commission no later
than the publication in the Federal
Register of such determinations by the
Department of Commerce.’’
Subsequently, the Department of
Commerce extended the date for its final
determination in the investigation on
Mexico to June 13, 2008 (73 FR 10743,
February 28, 2008). The Commission is,
hereby, issuing its additional scheduling
date with respect to the investigations
concerning China, Korea, and Mexico as
follows: a supplemental brief addressing
only Commerce’s final countervailing
and antidumping duty determinations is
due on June 20, 2008. The brief may not
exceed five (5) pages in length.
For further information concerning
these investigations see the
Commission’s notice cited above and
the Commission’s Rules of Practice and
Procedure, part 201, subparts A through
E (19 CFR part 201), and part 207,
subparts A and C (19 CFR part 207).
Authority: These investigations are being
conducted under authority of title VII of the
Tariff Act of 1930; this notice is published
pursuant to section 207.21 of the
Commission’s rules.
By order of the Commission.
Issued: April 28, 2008.
Marilyn R. Abbott,
Secretary to the Commission.
[FR Doc. E8–9665 Filed 5–1–08; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
mstockstill on PROD1PC66 with NOTICES
Notice of Lodging of Consent Decree
Under the Clean Air Act
Notice is hereby given that on April
24, 2008, a proposed Consent Decree
(‘‘Decree’’) in United States v.
McCulloch Corporation, et al., Civil
Action No. 1:08–cv–00699, was lodged
with the United States District Court for
the District of Columbia.
In this action the United States, on
behalf of the U.S. Environmental
Protection Agency (‘‘U.S. EPA’’), sought
penalties and injunctive relief under
sections 204, 205, and 213 of the Clean
Air Act (‘‘the Act’’ or ‘‘CAA’’), 42 U.S.C.
7523, 7524, and 7547, and regulations
promulgated thereunder at 40 CFR part
90 (‘‘Nonroad SI Regulations’’), which
arose from the importation and
introduction into commerce of
approximately 200,000 chainsaws
(‘‘subject chainsaws’’) that failed to
comply with the Nonroad SI
Regulations. The proposed Decree
resolves alleged violations of the CAA
arising from the importation of the
subject chainsaws. Under the Decree,
Defendants will pay a $2 million civil
VerDate Aug<31>2005
17:17 May 01, 2008
Jkt 214001
penalty, export unsold chainsaws,
perform emissions testing on a
representative sampling of engines, and
implement robust compliance assurance
plans designed to prevent future
violations. Defendants will also perform
the following three mitigation projects
at an estimated cost of $5 million: (1)
Spend at least $2.75 million to provide
light-emitting diode (‘‘LED’’)
streetlights, sport lights or parking lot
lights to selected cities in the United
States, (2) spend at least $1.25 million
to purchase and then surrender to U.S.
EPA Ozone Season NOX Allowances,
and (3) install low-permeable fuel lines
that will prevent or reduce volatile
organic compound permeation
emissions in at least 1 million small,
spark-ignited engines used for handheld
lawn and garden applications.
The Department of Justice will receive
for a period of thirty (30) days from the
date of this publication comments
relating to the Decree. Comments should
be addressed to the Assistant Attorney
General, Environment and Natural
Resources Division, P.O. Box 7611, U.S.
Department of Justice, Washington, D.C.
20044–7611, and either e-mailed to
pubcomment-ees.enrd@usdoj.gov or
mailed to P.O. Box 7611, U.S.
Department of Justice, Washington, DC
20044–7611, and should refer to United
States v. McCulloch Corporation et al.,
D.J. Ref. 90–5–2–1–09103. The Decree
may be examined at U.S. EPA, Office of
Enforcement and Compliance
Assurance, Western Field Office
(8MSU), 1595 Wynkoop Street, Denver,
CO 80202. During the public comment
period, the Decree may also be
examined on the following Department
of Justice Web site, https://
www.usdoj.gov/enrd/Consent_
Decrees.html. A copy of the Decree may
also be obtained by mail from the
Consent Decree Library, P.O. Box 7611,
U.S. Department of Justice, Washington,
DC 20044–7611 or by faxing or emailing a request to Tonia Fleetwood
(tonia.fleetwood@usdoj.gov), fax no.
(202) 514–0097, phone confirmation
number (202) 514–1547. In requesting a
copy from the Consent Decree Library,
please enclose a check in the amount of
$16.25 (25 cents per page reproduction
cost) payable to the U.S. Treasury or, if
by e-mail or fax, forward a check in that
amount to the Consent Decree Library at
the stated address.
DEPARTMENT OF JUSTICE
Karen Dworkin,
Assistant Chief, Environmental Enforcement
Section, Environment and Natural Resources
Division.
[FR Doc. E8–9677 Filed 5–1–08; 8:45 am]
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on April 2, 2008, Lin
Zhi International Inc., 687 North
Pastoria Avenue, Sunnyvale, California
94085, made application by renewal to
BILLING CODE 4410–15–P
PO 00000
Frm 00103
Fmt 4703
Sfmt 4703
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on April 3, 2008,
Abbott Laboratories, DBA Knoll
Pharmaceutical Company, 30 North
Jefferson Road, Whippany, New Jersey
07981, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in
schedules I and II:
Drug
Dihydromorphine (9145) ...............
Hydromorphone (9150) ................
Schedule
I
II
The company plans to manufacture
bulk product and dosage units for
distribution to its customers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such substances
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR § 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), Washington, DC 20537, or any
being sent via express mail should be
sent to Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than July 1, 2008.
Dated: April 28, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–9696 Filed 5–1–08; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
E:\FR\FM\02MYN1.SGM
02MYN1
]]>Agencies
[Federal Register Volume 73, Number 86 (Friday, May 2, 2008)]
[Notices]
[Page 24313]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-9696]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on April 3, 2008, Abbott
Laboratories, DBA Knoll Pharmaceutical Company, 30 North Jefferson
Road, Whippany, New Jersey 07981, made application by renewal to the
Drug Enforcement Administration (DEA) to be registered as a bulk
manufacturer of the basic classes of controlled substances listed in
schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Dihydromorphine (9145)..................... I
Hydromorphone (9150)....................... II
------------------------------------------------------------------------
The company plans to manufacture bulk product and dosage units for
distribution to its customers.
Any other such applicant and any person who is presently registered
with DEA to manufacture such substances may file comments or objections
to the issuance of the proposed registration pursuant to 21 CFR Sec.
1301.33(a).
Any such written comments or objections being sent via regular mail
should be addressed, in quintuplicate, to the Drug Enforcement
Administration, Office of Diversion Control, Federal Register
Representative (ODL), Washington, DC 20537, or any being sent via
express mail should be sent to Drug Enforcement Administration, Office
of Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than July 1, 2008.
Dated: April 28, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E8-9696 Filed 5-1-08; 8:45 am]
BILLING CODE 4410-09-P
